Track NuCana plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NuCana plc NCNA Open NuCana plc in new tab

1.63 USD
P/E
0.00
EPS
399.39
P/B
0.21
ROE
-181.81
Beta
1.71
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 14, 2026
P/E0.00
EPS399.39
Book Value8.32
Price to Book0.21
Debt/Equity0.53
% Insiders0.001%
Estimates
Forward P/E-0.18
Forward EPS-9.43

DCF Valuation

Tweak assumptions to recompute fair value for NuCana plc (NCNA)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NuCana plc Logo NuCana plc Analysis (NCNA)

United Kingdom Health Care Official Website Stock

Is NuCana plc a good investment? NuCana plc (NCNA) is currently trading at 1.63 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that NuCana plc is undervalued compared to historical market norms.

Earnings Schedule: NuCana plc is expected to release its next earnings report on May 14, 2026. The market consensus estimate for Forward EPS is -9.43.

Investor FAQ

Does NuCana plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is NuCana plc?

NuCana plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 14, 2026. The company currently has a trailing EPS of 399.39.

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Exchange Ticker
NMS (United States) NCNA

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
April 16, 2024 0.040000
Aug. 8, 2025 0.010000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion